Drug intelligence / Profile preview

tairilafon

Development stage: Unknown
Lead developer: Nanjing Zhongrui Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Tairilafon is a small molecule free radical scavenger developed by Nanjing Zhongrui Pharmaceutical for the treatment of acute cerebral infarction (ischemic stroke). It is a derivative of edaravone, designed to improve the pharmacological profile of the parent compound. Tairilafon works by scavenging reactive oxygen species (ROS) and inhibiting lipid peroxidation, thereby protecting neuronal cells from oxidative stress and apoptosis during the reperfusion phase following an ischemic event. The drug is formulated for intravenous administration and has been investigated in Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.

Other names: 泰瑞拉奉Edaravone phosphate

Beyond the preview

Go deeper on tairilafon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tairilafon.

Explore the full profile